Suspended PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05643729

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of ZofinTM for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: ZEO ScientifiX, Inc.

Conditions COPD

Interventions Placebo Zofin

Updated 7 times since 2023 Last updated: Oct 30, 2023 Started: Nov 15, 2023 Primary completion: May 30, 2024 Completion: Aug 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Study is on hold

This PHASE1/PHASE2 trial investigates COPD and is currently suspended. ZEO ScientifiX, Inc. leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Suspended PHASE1_PHASE2
Dec 2023 — May 2024 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended
Apr 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Jan 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ZEO ScientifiX, Inc.

Data source: ZEO ScientifiX, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Phoenix, United States